Negotiated Medicare prices for 15 additional drugs, including Ozempic and Keytruda, take effect

Negotiated prices for the second round of 15 Medicare Part D drugs take effect, including Ozempic/Wegovy (semaglutide), Keytruda (pembrolizumab), Biktarvy, and Vyvanse. The second round covers the most expensive and widely used specialty drugs, including blockbuster cancer and diabetes treatments. CBO projects cumulative savings of $100B+ for Medicare over 10 years from both rounds combined. The OBBBA's expanded orphan drug exclusion may reduce the number of drugs eligible for future negotiation rounds.